Author Archives: Warren Woessner

Supreme Court Voids Amgen’s Patents using “Undue Experimentation” Standard

Posted on May 22, 2023 by Warren Woessner

In Appeal no. 21-257 (May 18, 2023), the Supreme Court affirmed the judgement of the Fed. Cir. by ruling that all of the claims of Amgen’s U.S. Patent nos. 8,829,165 and 8,859, 741 were invalid due to their failure to … Continue reading →

Posted in Enablement | Tagged , , , | Leave a comment

From SLW International: Info on the Unitary Patent and the Unified Patent Court

Posted on April 27, 2023 by Warren Woessner

Guest contribution from SLW International: A short paper with information on the Unitary Patent and the Unified Patent Court can be found here.

Posted in EP and UK Practice, Int'l Practice and Policy, Non-U.S. Practice, Uncategorized | Tagged , , | Leave a comment

Chromadex v. Elysium Health – It’s Only Natural!

Posted on February 24, 2023 by Warren Woessner

On February 13, 2023, a Fed. Cir. panel of Judges Prost, Chen and Stoll (Prost writing) held, in Appeal no. 2022-1116, that the asserted claims 1-3 of U.S. Patent No. 8,197, 807 are directed to unpatentable subject matter, namely to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

“Inequitable Conduct: Refresher and Update” Panel on March 16

Posted on February 23, 2023 by Warren Woessner

I will be on a panel,  “Inequitable Conduct: Refresher and Update,” with Danny Huntington of Rothwell Figg and William Covey of the PTO OED. The panel will take place on Thursday, March 16 at the 2023 IPOwners Spring SummitTM in … Continue reading →

Posted in Inequitable Conduct/Rule 56, Uncategorized | Tagged , , , | Leave a comment